Arch Biopartners Stock Performance
| ARCH Stock | CAD 1.95 0.01 0.51% |
On a scale of 0 to 100, Arch Biopartners holds a performance score of 15. The firm shows a Beta (market volatility) of 0.26, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Arch Biopartners' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arch Biopartners is expected to be smaller as well. Please check Arch Biopartners' semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to make a quick decision on whether Arch Biopartners' price patterns will revert.
Risk-Adjusted Performance
15 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Arch Biopartners are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal fundamental indicators, Arch Biopartners showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:3 | Ex Dividend Date 2000-09-13 | Last Split Date 2003-11-25 |
1 | Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - ... | 11/11/2024 |
| Begin Period Cash Flow | 506.3 K |
Arch |
Arch Biopartners Relative Risk vs. Return Landscape
If you would invest 141.00 in Arch Biopartners on September 3, 2024 and sell it today you would earn a total of 54.00 from holding Arch Biopartners or generate 38.3% return on investment over 90 days. Arch Biopartners is generating 0.5433% of daily returns assuming 2.6891% volatility of returns over the 90 days investment horizon. Simply put, 23% of all stocks have less volatile historical return distribution than Arch Biopartners, and 90% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Arch Biopartners Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arch Biopartners' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arch Biopartners, and traders can use it to determine the average amount a Arch Biopartners' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.202
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ARCH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.69 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.54 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Arch Biopartners is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arch Biopartners by adding it to a well-diversified portfolio.
Arch Biopartners Fundamentals Growth
Arch Stock prices reflect investors' perceptions of the future prospects and financial health of Arch Biopartners, and Arch Biopartners fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arch Stock performance.
| Return On Asset | -0.81 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | 131.58 M | ||||
| Shares Outstanding | 64.94 M | ||||
| Price To Sales | 91.99 X | ||||
| Revenue | 1.98 M | ||||
| Gross Profit | (502.88 K) | ||||
| EBITDA | (5.24 M) | ||||
| Net Income | (3.33 M) | ||||
| Cash And Equivalents | 72.82 K | ||||
| Total Debt | 5.02 M | ||||
| Current Ratio | 0.32 X | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (234.07 K) | ||||
| Earnings Per Share | (0.03) X | ||||
| Market Capitalization | 129.88 M | ||||
| Total Asset | 1.17 M | ||||
| Retained Earnings | (28.05 M) | ||||
| Working Capital | (4.81 M) | ||||
About Arch Biopartners Performance
Evaluating Arch Biopartners' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Arch Biopartners has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arch Biopartners has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 28.22 | 29.63 | |
| Return On Tangible Assets | -2.9 K | -2.8 K | |
| Return On Capital Employed | 0.53 | 0.50 | |
| Return On Assets | -2.9 K | -2.8 K | |
| Return On Equity | 13.46 | 14.13 |
Things to note about Arch Biopartners performance evaluation
Checking the ongoing alerts about Arch Biopartners for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arch Biopartners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arch Biopartners may become a speculative penny stock | |
| Arch Biopartners has accumulated 5.02 M in total debt. Arch Biopartners has a current ratio of 0.31, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.98 M. Net Loss for the year was (3.33 M) with loss before overhead, payroll, taxes, and interest of (502.88 K). | |
| Arch Biopartners has accumulated about 72.82 K in cash with (234.07 K) of positive cash flow from operations. | |
| Roughly 20.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - Yahoo Finance |
- Analyzing Arch Biopartners' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arch Biopartners' stock is overvalued or undervalued compared to its peers.
- Examining Arch Biopartners' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arch Biopartners' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arch Biopartners' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arch Biopartners' stock. These opinions can provide insight into Arch Biopartners' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.